U.S. markets closed
  • S&P 500

    4,411.79
    +44.31 (+1.01%)
     
  • Dow 30

    35,061.55
    +238.20 (+0.68%)
     
  • Nasdaq

    14,836.99
    +152.39 (+1.04%)
     
  • Russell 2000

    2,209.65
    +10.17 (+0.46%)
     
  • Crude Oil

    72.17
    +0.26 (+0.36%)
     
  • Gold

    1,802.10
    -3.30 (-0.18%)
     
  • Silver

    25.24
    -0.14 (-0.56%)
     
  • EUR/USD

    1.1770
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • GBP/USD

    1.3754
    -0.0013 (-0.10%)
     
  • USD/JPY

    110.5100
    +0.3950 (+0.36%)
     
  • BTC-USD

    33,677.36
    +1,022.15 (+3.13%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) plans to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC1).

  • Tonix plans to meet the FDA in Q3 of 2021 to seek agreement on designing a potential Phase 2 study and the overall clinical development plan.

  • TNX-102 SL is in the second Phase 3 trial (RALLY) for fibromyalgia. The interim analysis results are expected in Q3 of 2021, and topline results in Q1 of 2022.

  • Earlier this month, data from the Phase 3 RELIEF trial in fibromyalgia showed TNX-102 SL significantly reduced daily pain compared to placebo and improved sleep quality, mitigation of fatigue, and fibromyalgia-specific functional recovery.

  • Price Action: TNXP shares are up 3.28% at $1.26 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.